132 related articles for article (PubMed ID: 33597819)
1. The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells.
DoĞan E; DÜzgÜn Z; Yildirim Z; Özdİl B; AktuĞ H; Bozok ÇetİntaŞ V
Turk J Biol; 2021; 45(1):26-34. PubMed ID: 33597819
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy.
Hou JZ; Xi ZQ; Niu J; Li W; Wang X; Liang C; Sun H; Fang D; Xie SQ
Oncol Rep; 2019 Mar; 41(3):1971-1979. PubMed ID: 30569119
[TBL] [Abstract][Full Text] [Related]
3. The PIKfyve inhibitor YM201636 blocks the continuous recycling of the tight junction proteins claudin-1 and claudin-2 in MDCK cells.
Dukes JD; Whitley P; Chalmers AD
PLoS One; 2012; 7(3):e28659. PubMed ID: 22396724
[TBL] [Abstract][Full Text] [Related]
4. Functional dissociation between PIKfyve-synthesized PtdIns5P and PtdIns(3,5)P2 by means of the PIKfyve inhibitor YM201636.
Sbrissa D; Ikonomov OC; Filios C; Delvecchio K; Shisheva A
Am J Physiol Cell Physiol; 2012 Aug; 303(4):C436-46. PubMed ID: 22621786
[TBL] [Abstract][Full Text] [Related]
5. Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin.
Piontek A; Eichner M; Zwanziger D; Beier LS; Protze J; Walther W; Theurer S; Schmid KW; Führer-Sakel D; Piontek J; Krause G
Mol Oncol; 2020 Feb; 14(2):261-276. PubMed ID: 31825142
[TBL] [Abstract][Full Text] [Related]
6. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
8. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
[TBL] [Abstract][Full Text] [Related]
9. PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1.
Oppelt A; Haugsten EM; Zech T; Danielsen HE; Sveen A; Lobert VH; Skotheim RI; Wesche J
Biochem J; 2014 Aug; 461(3):383-90. PubMed ID: 24840251
[TBL] [Abstract][Full Text] [Related]
10. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.
Kudinov AE; Deneka A; Nikonova AS; Beck TN; Ahn YH; Liu X; Martinez CF; Schultz FA; Reynolds S; Yang DH; Cai KQ; Yaghmour KM; Baker KA; Egleston BL; Nicolas E; Chikwem A; Andrianov G; Singh S; Borghaei H; Serebriiskii IG; Gibbons DL; Kurie JM; Golemis EA; Boumber Y
Proc Natl Acad Sci U S A; 2016 Jun; 113(25):6955-60. PubMed ID: 27274057
[TBL] [Abstract][Full Text] [Related]
11. Active vacuolar H+ ATPase and functional cycle of Rab5 are required for the vacuolation defect triggered by PtdIns(3,5)P2 loss under PIKfyve or Vps34 deficiency.
Compton LM; Ikonomov OC; Sbrissa D; Garg P; Shisheva A
Am J Physiol Cell Physiol; 2016 Sep; 311(3):C366-77. PubMed ID: 27335171
[TBL] [Abstract][Full Text] [Related]
12. Polar and charged extracellular residues conserved among barrier-forming claudins contribute to tight junction strand formation.
Piontek A; Rossa J; Protze J; Wolburg H; Hempel C; Günzel D; Krause G; Piontek J
Ann N Y Acad Sci; 2017 Jun; 1397(1):143-156. PubMed ID: 28415153
[TBL] [Abstract][Full Text] [Related]
13. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
[TBL] [Abstract][Full Text] [Related]
14. Identification of PIKfyve kinase as a target in multiple myeloma.
de Campos CB; Zhu YX; Sepetov N; Romanov S; Bruins LA; Shi CX; Stein CK; Petit JL; Polito AN; Sharik ME; Meermeier EW; Ahmann GJ; Armenta IDL; Kruse J; Bergsagel PL; Chesi M; Meurice N; Braggio E; Stewart AK
Haematologica; 2020 Jun; 105(6):1641-1649. PubMed ID: 31582538
[TBL] [Abstract][Full Text] [Related]
15. EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non‑small cell lung cancer cells.
Lin C; Qin Y; Zhang H; Gao MY; Wang YF
Oncol Rep; 2018 Jul; 40(1):29-38. PubMed ID: 29749533
[TBL] [Abstract][Full Text] [Related]
16. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
17. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
18. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
19. Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma.
Akizuki R; Shimobaba S; Matsunaga T; Endo S; Ikari A
Biochim Biophys Acta Mol Cell Res; 2017 Feb; 1864(2):293-302. PubMed ID: 27884700
[TBL] [Abstract][Full Text] [Related]
20. Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
Sano O; Kazetani K; Funata M; Fukuda Y; Matsui J; Iwata H
FEBS Lett; 2016 Jun; 590(11):1576-85. PubMed ID: 27135648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
